Q2041 Medicaid Rate by State

Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

16 state Medicaid programs publish a fee-for-service rate for Q2041 (axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose), ranging from $387,472.40 in Delaware to $576,345.00 in Indiana among rates on the same basis.

Every state, kept current

Every code in every state: the Rates plan

$29 /mo, 7-day free trial

  • Every code on all 51 published schedules
  • Full-schedule CSV export and state network lists
  • Email alerts when a state changes its rates
Start free trial$29/mo after the trial; a trial exports 50-row samples

Or one file, no account: State-Specific Services across 45 states, 1,475 codes.

2026-11-19 edition, standardized by ProviderSignal. Secure checkout by Stripe; download link by email, 5 downloads in 30 days. License · Every file we sell

Publishing states

16

Median % of Medicare

--

Rate range, like rates

$387,472.40 - $576,345.00

Q2041 rates in every publishing state

  • Arkansas$454,860.00

    2026

  • Arizona$562,500.89

    2026

  • California$88,641.52

    Far below other states: the unit may differ.

    2026

  • District of Columbia$532,192.24

    Prior auth: required, 2026

  • Delaware$387,472.40

    2026

  • Idaho$459,814.10

    Prior auth: required, 2026

  • Indiana$576,345.00

    Prior auth: required, 2026

  • Kansas$562,500.89

    2026

  • Michigan$562,500.89

    2026

  • Mississippi$532,192.24

    2026

  • Montana$532,192.24

    2026

  • New Hampshire$548,900.00

    Prior auth: required, 2026

  • Rhode Island$537,054.07

    hospital outpatient payment

    2026

  • South Carolina$5,625.01

    Far below other states: the unit may differ.

    2026

  • Texas$533,076.48

    ages 18 and up

    2026

  • Virginia$562,500.89

    ages 18 and up

    2026

Published Medicaid fee-for-service schedule amounts, not a coverage or eligibility guarantee. Managed-care plan rates can differ. Where no prior-authorization flag is shown, the state does not publish one. A state that lists the code more than one way shows one of its rows here, with its basis: a rental is not a purchase price. "--" in the prior-auth column means the state publishes no PA flag.

Related state-specific services codes

All 12 codes from Q2009 to Q2058 or every state-specific services code by number.

Frequently asked questions

How much does Medicaid pay for Q2041?

16 state Medicaid programs publish a fee-for-service rate for Q2041 (axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose), ranging from $387,472.40 in Delaware to $576,345.00 in Indiana among rates on the same basis. The full table on this page lists every publishing state's current rate.

Which state pays the most for Q2041?

Indiana publishes the highest Medicaid rate for Q2041 at $576,345.00. Delaware publishes the lowest at $387,472.40, among rates on the same basis; rentals and rates far from the other states' are in the table with their basis.

Does Q2041 require prior authorization under Medicaid?

4 of the 16 publishing states flag Q2041 as requiring prior authorization (always or conditionally) on their fee schedules. States without a flag publish no PA indicator for this code - that means "not published", not "no PA required".